D. Bigner

发表

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

A. Friedman, E. Lipp, H. Friedman, 2012, British Journal of Cancer.

A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC).

D. Bigner, Henry S. Friedman, Qing Dong, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Mutations of the BRAF gene in human cancer

A. Nicholson, P. Futreal, R. Wooster, 2002, Nature.

Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.

O D Laerum, P. Humphrey, S. Bigner, 1990, Cancer research.

Gene expression profiling and genetic markers in glioblastoma survival.

M. West, H. Dressman, J. Nevins, 2005, Cancer research.

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

R. McLendon, A. Friedman, M. Dolan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

M M Haglund, T Kerby, R. McLendon, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of various methods for delivering radiolabeled monoclonal antibody to normal rat brain.

D. Bigner, D. Bullard, M. Bourdon, 1984, Journal of neurosurgery.

Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Mitchel S Berger, Allan H Friedman, James M Provenzale, 2008, Neuro-oncology.

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

R. Coleman, R. McLendon, A. Friedman, 2008, Neuro-oncology.

Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.

R. McLendon, A. Friedman, I. Pastan, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.

D. Bigner, M. Zalutsky, C. Foulon, 1999, Nuclear medicine and biology.

In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.

D. Bigner, S. Batra, M. Zalutsky, 1997, Nuclear medicine and biology.

Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.

D. Bigner, M. Zalutsky, C. Reist, 1997, Cancer research.

Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.

R. Coleman, R. McLendon, A. Friedman, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG

D. Bigner, S. Bigner, C. Wikstrand, 1984, Journal of Neuroimmunology.

Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.

R. McLendon, E. Thompson, E. Lipp, 2023, The Lancet. Child & adolescent health.

Central nervous system.

R. McLendon, D. Bigner, B. Rasheed, 2010, Cancer biomarkers : section A of Disease markers.

Alterations of the TP53 gene in human gliomas.

R. McLendon, A. Friedman, D. Bigner, 1994, Cancer research.

Deletion of p16 and p15 genes in brain tumors.

K. Kinzler, B. Vogelstein, D. Bigner, 1994, Cancer research.

Immunoaffinity purification of human O6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies.

T. Brent, C. Pegram, M. V. von Wronski, 1990, Cancer research.

Busulfan therapy of central nervous system xenografts in athymic mice

S. Keir, D. Bigner, H. Friedman, 2004, Cancer Chemotherapy and Pharmacology.

Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma.

J. Kurtzberg, G. Felsberg, S. Schold, 1995, Medical and Pediatric Oncology.

A mechanism underlying the lack of a blood-brain barrier to peroxidase in virally induced brain tumors.

D. Bigner, T. Reese, M. Brightman, 1971, Journal of neuropathology and experimental neurology.

GD3 expression by cultured human tumor cells of neuroectodermal origin

J. Månsson, P. Fredman, C. Wikstrand, 2004, Acta Neuropathologica.

Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.

T. Bouldin, M. Mahaley, J. Whitaker, 1983, Journal of neurosurgery.

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.

R. McLendon, A. Friedman, M. Dolan, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.

I. Pastan, R. Beers, C. Pegram, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

S. Keir, P. Houghton, S. Bigner, 1997, Cancer research.

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts

C. B. Hare, S. Keir, D. Bigner, 1996, Cancer Chemotherapy and Pharmacology.

Activity of temozolomide in the treatment of central nervous system tumor xenografts.

M. Dolan, S. Keir, D. Bigner, 1995, Cancer research.

Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

R. Coleman, D. Bigner, H. Coakham, 1989, Cancer research.

Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.

D. Bigner, M. Zalutsky, M. Stabin, 1997, Nuclear medicine and biology.

O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.

P. Kleihues, H. Friedman, J. Swenberg, 1989, Journal of neurosurgery.

Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.

Raghu Raghavan, Christoph Pedain, Allan H Friedman, 2007, Neuro-oncology.

Treatment of patients with pineoblastoma with high dose cyclophosphamide.

R. McLendon, D. Bigner, L. Ferrell, 1996, Medical and pediatric oncology.

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.

J. Bowsher, R. Coleman, D. Bigner, 2004, Blood.

Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.

R. Coleman, A. Friedman, D. Bigner, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

D. Bigner, H. Friedman, P. Garg, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.

R. Coleman, D. Bigner, P. Humphrey, 1988, Cancer research.

Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D‐212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study

D. Bigner, H. Friedman, M. Herman, 1990, Neuropathology and applied neurobiology.

Tumor-specific peptide vaccination in newly-diagnosed patients with GBM.

A. Friedman, D. Bigner, K. Aldape, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.

R. McLendon, A. Friedman, D. Bigner, 1995, Oncogene.

Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function.

D. Bigner, N. Vick, D D Bigner, 1972, Journal of the neurological sciences.

Development of a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3.

D. Bigner, Ines Fallon, Henar Hernando, 2024, SLAS discovery : advancing life sciences R & D.

Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.

R. McLendon, D. Bigner, P. Garg, 1996, International journal of radiation oncology, biology, physics.

The genetic landscape of anaplastic astrocytoma

R. McLendon, A. Friedman, Siân Jones, 2013, Oncotarget.

A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits.

D. Bigner, J. Trojanowski, P. Burger, 1987, The American journal of pathology.

Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.

D. Bigner, G. Dranoff, J. Sampson, 1997, Neurosurgery.

Oncogene amplification in pediatric brain tumors.

A. Look, D. Bigner, P. Burger, 1990, Cancer research.

Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.

R. McLendon, A. Friedman, D. Bigner, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.